Leerink Partners Reiterates Outperform Rating on Eli Lilly (LLY)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/29/2026
- Wall St falls as bond yields test multi-decade highs
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Risk appetite remains concentrated in large-cap stocks, Citi says
- Netflix stock: Deutsche Bank gets bullish as valuation leaves room to run
- CarMax shares rise over 2% on strong earnings and revenue beat
- Bloom Energy shares fall on Oracle project halt
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Stocks fall as higher oil prices, Treasury yields weigh
- Oppenheimer sees AI software winners as focus shifts to ROI
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
Eli Lilly (LLY) PT Raised to $1,158 at Morgan Stanley
October 11, 2024 8:23 AM EDTMorgan Stanley analyst Terence Flynn raised the price target on Eli Lilly (NYSE: LLY) to $1,158.00 (from $1,106.00) while maintaining a Overweight rating.... More
Eli Lilly (LLY) PT Raised to $1,033 at Truist Securities
October 10, 2024 7:05 AM EDT(Updated - October 10, 2024 7:06 AM EDT)
Truist Securities analyst Robyn Karnauskas raised the price target on Eli Lilly (NYSE: LLY) to $1,033.00 (from $1,000.00) while maintaining a Buy rating.
The analyst commented: "Eli Lilly Model Update, PT goes to $1,033 from $1,000. We... More
